Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Prostate Cancer

PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer
Targeting the Prostatic Tumor Microenvironment With PLX3397, a Tumor-Associated Macrophage Inhibitor in Men With Unfavorable Risk Prostate Cancer Undergoing Radiation Therapy and Androgen Deprivation Therapy
Status: Enrolling
Updated:  11/29/2017
Karmanos Cancer Institute at McLaren Northern Michigan - Petoskey Radiation Oncology
mi
from
Petoskey, MI
PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer
Targeting the Prostatic Tumor Microenvironment With PLX3397, a Tumor-Associated Macrophage Inhibitor in Men With Unfavorable Risk Prostate Cancer Undergoing Radiation Therapy and Androgen Deprivation Therapy
Status: Enrolling
Updated: 11/29/2017
Karmanos Cancer Institute at McLaren Northern Michigan - Petoskey Radiation Oncology
mi
from
Petoskey, MI
Click here to add this to my saved trials
PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer
Targeting the Prostatic Tumor Microenvironment With PLX3397, a Tumor-Associated Macrophage Inhibitor in Men With Unfavorable Risk Prostate Cancer Undergoing Radiation Therapy and Androgen Deprivation Therapy
Status: Enrolling
Updated:  11/29/2017
Karmanos Cancer Institute at McLaren Northern Michigan- Petoskey Medical Oncology
mi
from
Petoskey, MI
PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer
Targeting the Prostatic Tumor Microenvironment With PLX3397, a Tumor-Associated Macrophage Inhibitor in Men With Unfavorable Risk Prostate Cancer Undergoing Radiation Therapy and Androgen Deprivation Therapy
Status: Enrolling
Updated: 11/29/2017
Karmanos Cancer Institute at McLaren Northern Michigan- Petoskey Medical Oncology
mi
from
Petoskey, MI
Click here to add this to my saved trials
Calcium-41 (41Ca) Chloride Aqueous Solution in Diagnosing Patients With Prostate Cancer and Bone Metastasis
Measurement of Ca Kinetics in Humans With Prostate Cancer-induced Bone Disease
Status: Enrolling
Updated:  12/1/2017
Lawrence Livermore National Laboratory
mi
from
Livermore, CA
Calcium-41 (41Ca) Chloride Aqueous Solution in Diagnosing Patients With Prostate Cancer and Bone Metastasis
Measurement of Ca Kinetics in Humans With Prostate Cancer-induced Bone Disease
Status: Enrolling
Updated: 12/1/2017
Lawrence Livermore National Laboratory
mi
from
Livermore, CA
Click here to add this to my saved trials
Abiraterone Post Ketoconazole for Prostate Cancer
A Phase II Study of Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer (CRPC) and Prior Therapy With Ketoconazole
Status: Enrolling
Updated:  12/6/2017
University of Chicago
mi
from
Chicago, IL
Abiraterone Post Ketoconazole for Prostate Cancer
A Phase II Study of Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer (CRPC) and Prior Therapy With Ketoconazole
Status: Enrolling
Updated: 12/6/2017
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Abiraterone Post Ketoconazole for Prostate Cancer
A Phase II Study of Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer (CRPC) and Prior Therapy With Ketoconazole
Status: Enrolling
Updated:  12/6/2017
University of California at San Francisco
mi
from
San Francisco, CA
Abiraterone Post Ketoconazole for Prostate Cancer
A Phase II Study of Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer (CRPC) and Prior Therapy With Ketoconazole
Status: Enrolling
Updated: 12/6/2017
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel
A Phase II Study of MAOA Inhibitor Plus Docetaxel in Patients Receiving and Progressing on Docetaxel Therapy
Status: Enrolling
Updated:  12/7/2017
OHSU Knight Cancer Institute
mi
from
Portland, OR
Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel
A Phase II Study of MAOA Inhibitor Plus Docetaxel in Patients Receiving and Progressing on Docetaxel Therapy
Status: Enrolling
Updated: 12/7/2017
OHSU Knight Cancer Institute
mi
from
Portland, OR
Click here to add this to my saved trials
Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel
A Phase II Study of MAOA Inhibitor Plus Docetaxel in Patients Receiving and Progressing on Docetaxel Therapy
Status: Enrolling
Updated:  12/7/2017
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel
A Phase II Study of MAOA Inhibitor Plus Docetaxel in Patients Receiving and Progressing on Docetaxel Therapy
Status: Enrolling
Updated: 12/7/2017
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel
A Phase II Study of MAOA Inhibitor Plus Docetaxel in Patients Receiving and Progressing on Docetaxel Therapy
Status: Enrolling
Updated:  12/7/2017
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel
A Phase II Study of MAOA Inhibitor Plus Docetaxel in Patients Receiving and Progressing on Docetaxel Therapy
Status: Enrolling
Updated: 12/7/2017
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
A Phase 1 Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
Status: Enrolling
Updated:  12/7/2017
Pinnacle Oncology Hematology
mi
from
Scottsdale, AZ
A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
A Phase 1 Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
Status: Enrolling
Updated: 12/7/2017
Pinnacle Oncology Hematology
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
A Phase 1 Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
Status: Enrolling
Updated:  12/7/2017
Yale University
mi
from
New Haven, CT
A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
A Phase 1 Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
Status: Enrolling
Updated: 12/7/2017
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
A Phase 1 Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
Status: Enrolling
Updated:  12/7/2017
Harvard-Mass General Hospital
mi
from
Boston, MA
A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
A Phase 1 Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
Status: Enrolling
Updated: 12/7/2017
Harvard-Mass General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
A Phase 1 Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
Status: Enrolling
Updated:  12/7/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
A Phase 1 Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
Status: Enrolling
Updated: 12/7/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
A Phase 1 Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
Status: Enrolling
Updated:  12/7/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
A Phase 1 Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
Status: Enrolling
Updated: 12/7/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
A Phase 1 Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
Status: Enrolling
Updated:  12/7/2017
Univ of Washington
mi
from
Seattle, WA
A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
A Phase 1 Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
Status: Enrolling
Updated: 12/7/2017
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral Sclerosis
Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  12/8/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral Sclerosis
Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 12/8/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Genistein in Treating Patients With Prostate Cancer
Phase 2 Trial of Genistein in Men With Circulating Prostate Cancer Cells
Status: Enrolling
Updated:  12/11/2017
Northwestern University
mi
from
Chicago, IL
Genistein in Treating Patients With Prostate Cancer
Phase 2 Trial of Genistein in Men With Circulating Prostate Cancer Cells
Status: Enrolling
Updated: 12/11/2017
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer
A Phase I Study of Niclosamide in Combination With Enzalutamide in Men With Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  12/11/2017
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer
A Phase I Study of Niclosamide in Combination With Enzalutamide in Men With Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 12/11/2017
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Antineoplaston Therapy in Treating Patients With Metastatic Prostate Cancer
Phase II Study of Antineoplaston A10 and AS2-1 in Patients With Adenocarcinoma of the Prostate
Status: Enrolling
Updated:  12/11/2017
Burzynski Clinic
mi
from
Houston, TX
Antineoplaston Therapy in Treating Patients With Metastatic Prostate Cancer
Phase II Study of Antineoplaston A10 and AS2-1 in Patients With Adenocarcinoma of the Prostate
Status: Enrolling
Updated: 12/11/2017
Burzynski Clinic
mi
from
Houston, TX
Click here to add this to my saved trials
Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
Phase II Study of Metformin in a Pre-prostatectomy Prostate Cancer Cohort
Status: Enrolling
Updated:  12/12/2017
University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
Phase II Study of Metformin in a Pre-prostatectomy Prostate Cancer Cohort
Status: Enrolling
Updated: 12/12/2017
University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
Phase II Study of Metformin in a Pre-prostatectomy Prostate Cancer Cohort
Status: Enrolling
Updated:  12/12/2017
Arizona Cancer Center - Tucson
mi
from
Tucson, AZ
Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
Phase II Study of Metformin in a Pre-prostatectomy Prostate Cancer Cohort
Status: Enrolling
Updated: 12/12/2017
Arizona Cancer Center - Tucson
mi
from
Tucson, AZ
Click here to add this to my saved trials
Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
Phase II Study of Metformin in a Pre-prostatectomy Prostate Cancer Cohort
Status: Enrolling
Updated:  12/12/2017
University of Southern California/Norris Cancer Center
mi
from
Los Angeles, CA
Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
Phase II Study of Metformin in a Pre-prostatectomy Prostate Cancer Cohort
Status: Enrolling
Updated: 12/12/2017
University of Southern California/Norris Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Exercise for Prostate Cancer Patients
The Influence of Home-based Aerobic and Resistance Exercise on Cancer-Related Fatigue, Strength, and Muscle Mass in Prostate Patients.
Status: Enrolling
Updated:  12/13/2017
James P. Wilmot Cancer Center, University of Rochester
mi
from
Rochester, NY
Exercise for Prostate Cancer Patients
The Influence of Home-based Aerobic and Resistance Exercise on Cancer-Related Fatigue, Strength, and Muscle Mass in Prostate Patients.
Status: Enrolling
Updated: 12/13/2017
James P. Wilmot Cancer Center, University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
Decision Support Tools for Men With Prostate Cancer- Clinical & Lifestyle Model
Development, Validation, and Dissemination of an Integrated Risk Prediction Model and Decision Aid to Discern Aggressive vs Indolent Prostate Cancer (Aim 2A)
Status: Enrolling
Updated:  12/13/2017
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Decision Support Tools for Men With Prostate Cancer- Clinical & Lifestyle Model
Development, Validation, and Dissemination of an Integrated Risk Prediction Model and Decision Aid to Discern Aggressive vs Indolent Prostate Cancer (Aim 2A)
Status: Enrolling
Updated: 12/13/2017
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Decision Support Tools for Men With Prostate Cancer- Clinical & Lifestyle Model
Development, Validation, and Dissemination of an Integrated Risk Prediction Model and Decision Aid to Discern Aggressive vs Indolent Prostate Cancer (Aim 2A)
Status: Enrolling
Updated:  12/13/2017
University of California, San Francisco (SFGH)
mi
from
San Francisco, CA
Decision Support Tools for Men With Prostate Cancer- Clinical & Lifestyle Model
Development, Validation, and Dissemination of an Integrated Risk Prediction Model and Decision Aid to Discern Aggressive vs Indolent Prostate Cancer (Aim 2A)
Status: Enrolling
Updated: 12/13/2017
University of California, San Francisco (SFGH)
mi
from
San Francisco, CA
Click here to add this to my saved trials
North Carolina Prostate Cancer Comparative Effectiveness & Survivorship Study (NC ProCESS)
Status: Enrolling
Updated:  12/13/2017
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
North Carolina Prostate Cancer Comparative Effectiveness & Survivorship Study (NC ProCESS)
Status: Enrolling
Updated: 12/13/2017
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer
Multi-Centre, Ph IIb Study, Evaluating Safety & Efficacy of Targeted Intraprostatic Admin of PRX302 to Treat Men With Histologically Proven, Clinically Significant, Localised Prostate Cancer Associated With MRI Lesion
Status: Enrolling
Updated:  12/13/2017
Vantage Health
mi
from
Ocala, FL
Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer
Multi-Centre, Ph IIb Study, Evaluating Safety & Efficacy of Targeted Intraprostatic Admin of PRX302 to Treat Men With Histologically Proven, Clinically Significant, Localised Prostate Cancer Associated With MRI Lesion
Status: Enrolling
Updated: 12/13/2017
Vantage Health
mi
from
Ocala, FL
Click here to add this to my saved trials
Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer
Multi-Centre, Ph IIb Study, Evaluating Safety & Efficacy of Targeted Intraprostatic Admin of PRX302 to Treat Men With Histologically Proven, Clinically Significant, Localised Prostate Cancer Associated With MRI Lesion
Status: Enrolling
Updated:  12/13/2017
Chesapeake Urology Associates
mi
from
Baltimore, MD
Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer
Multi-Centre, Ph IIb Study, Evaluating Safety & Efficacy of Targeted Intraprostatic Admin of PRX302 to Treat Men With Histologically Proven, Clinically Significant, Localised Prostate Cancer Associated With MRI Lesion
Status: Enrolling
Updated: 12/13/2017
Chesapeake Urology Associates
mi
from
Baltimore, MD
Click here to add this to my saved trials
Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer
Multi-Centre, Ph IIb Study, Evaluating Safety & Efficacy of Targeted Intraprostatic Admin of PRX302 to Treat Men With Histologically Proven, Clinically Significant, Localised Prostate Cancer Associated With MRI Lesion
Status: Enrolling
Updated:  12/13/2017
New York Urology Associates
mi
from
New York, NY
Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer
Multi-Centre, Ph IIb Study, Evaluating Safety & Efficacy of Targeted Intraprostatic Admin of PRX302 to Treat Men With Histologically Proven, Clinically Significant, Localised Prostate Cancer Associated With MRI Lesion
Status: Enrolling
Updated: 12/13/2017
New York Urology Associates
mi
from
New York, NY
Click here to add this to my saved trials
Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer
Multi-Centre, Ph IIb Study, Evaluating Safety & Efficacy of Targeted Intraprostatic Admin of PRX302 to Treat Men With Histologically Proven, Clinically Significant, Localised Prostate Cancer Associated With MRI Lesion
Status: Enrolling
Updated:  12/13/2017
Baylor Scott & White Memorial Hospital and Clinic
mi
from
Temple, TX
Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer
Multi-Centre, Ph IIb Study, Evaluating Safety & Efficacy of Targeted Intraprostatic Admin of PRX302 to Treat Men With Histologically Proven, Clinically Significant, Localised Prostate Cancer Associated With MRI Lesion
Status: Enrolling
Updated: 12/13/2017
Baylor Scott & White Memorial Hospital and Clinic
mi
from
Temple, TX
Click here to add this to my saved trials
Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer
Multi-Centre, Ph IIb Study, Evaluating Safety & Efficacy of Targeted Intraprostatic Admin of PRX302 to Treat Men With Histologically Proven, Clinically Significant, Localised Prostate Cancer Associated With MRI Lesion
Status: Enrolling
Updated:  12/13/2017
Princess Alexandra Hospital
mi
from
Harlow,
Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer
Multi-Centre, Ph IIb Study, Evaluating Safety & Efficacy of Targeted Intraprostatic Admin of PRX302 to Treat Men With Histologically Proven, Clinically Significant, Localised Prostate Cancer Associated With MRI Lesion
Status: Enrolling
Updated: 12/13/2017
Princess Alexandra Hospital
mi
from
Harlow,
Click here to add this to my saved trials
A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
A Phase II Trial of the Aurora Kinase A Inhibitor MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
Status: Enrolling
Updated:  12/18/2017
University of Chicago
mi
from
Chicago, IL
A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
A Phase II Trial of the Aurora Kinase A Inhibitor MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
Status: Enrolling
Updated: 12/18/2017
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
A Phase II Trial of the Aurora Kinase A Inhibitor MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
Status: Enrolling
Updated:  12/18/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
A Phase II Trial of the Aurora Kinase A Inhibitor MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
Status: Enrolling
Updated: 12/18/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
A Phase II Trial of the Aurora Kinase A Inhibitor MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
Status: Enrolling
Updated:  12/18/2017
Duke University Health System
mi
from
Durham, NC
A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
A Phase II Trial of the Aurora Kinase A Inhibitor MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
Status: Enrolling
Updated: 12/18/2017
Duke University Health System
mi
from
Durham, NC
Click here to add this to my saved trials
A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
A Phase II Trial of the Aurora Kinase A Inhibitor MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
Status: Enrolling
Updated:  12/18/2017
University of Washington Medical Center
mi
from
Seattle, WA
A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
A Phase II Trial of the Aurora Kinase A Inhibitor MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
Status: Enrolling
Updated: 12/18/2017
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
A Phase II Trial of the Aurora Kinase A Inhibitor MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
Status: Enrolling
Updated:  12/18/2017
Karmanos Cancer Institute
mi
from
Detroit, MI
A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
A Phase II Trial of the Aurora Kinase A Inhibitor MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
Status: Enrolling
Updated: 12/18/2017
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
A Phase II Trial of the Aurora Kinase A Inhibitor MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
Status: Enrolling
Updated:  12/18/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
A Phase II Trial of the Aurora Kinase A Inhibitor MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
Status: Enrolling
Updated: 12/18/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
A Phase II Trial of the Aurora Kinase A Inhibitor MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
Status: Enrolling
Updated:  12/18/2017
Weill-Cornell Medical College
mi
from
New York, NY
A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
A Phase II Trial of the Aurora Kinase A Inhibitor MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
Status: Enrolling
Updated: 12/18/2017
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
A Phase II Trial of the Aurora Kinase A Inhibitor MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
Status: Enrolling
Updated:  12/18/2017
University Hospitals of Cleveland Medical Center
mi
from
Cleveland, OH
A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
A Phase II Trial of the Aurora Kinase A Inhibitor MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
Status: Enrolling
Updated: 12/18/2017
University Hospitals of Cleveland Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
MRI Before Biopsy in Diagnosing Patients With Prostate Cancer
Novel Screening MRI for the Detection of Prostate Cancer
Status: Enrolling
Updated:  12/19/2017
University Hospitals, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
MRI Before Biopsy in Diagnosing Patients With Prostate Cancer
Novel Screening MRI for the Detection of Prostate Cancer
Status: Enrolling
Updated: 12/19/2017
University Hospitals, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastasis
A Pharmacodynamic Study Using NaF PET/CT Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Metastatic Castrate Resistant Prostate Cancer to Bone
Status: Enrolling
Updated:  12/20/2017
University of Wisconsin Carbone Cancer Center
mi
from
Madison, WI
NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastasis
A Pharmacodynamic Study Using NaF PET/CT Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Metastatic Castrate Resistant Prostate Cancer to Bone
Status: Enrolling
Updated: 12/20/2017
University of Wisconsin Carbone Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Prostatectomy Prospective Database
Prostatectomy Database
Status: Enrolling
Updated:  12/21/2017
William Beaumont Hospital
mi
from
Royal Oak, MI
Prostatectomy Prospective Database
Prostatectomy Database
Status: Enrolling
Updated: 12/21/2017
William Beaumont Hospital
mi
from
Royal Oak, MI
Click here to add this to my saved trials
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical Prostatectomy
Status: Enrolling
Updated:  12/21/2017
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical Prostatectomy
Status: Enrolling
Updated: 12/21/2017
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical Prostatectomy
Status: Enrolling
Updated:  12/21/2017
Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital
mi
from
Fairbanks, AK
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical Prostatectomy
Status: Enrolling
Updated: 12/21/2017
Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital
mi
from
Fairbanks, AK
Click here to add this to my saved trials
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical Prostatectomy
Status: Enrolling
Updated:  12/21/2017
Arizona Center for Cancer Care - Peoria
mi
from
Peoria, AZ
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical Prostatectomy
Status: Enrolling
Updated: 12/21/2017
Arizona Center for Cancer Care - Peoria
mi
from
Peoria, AZ
Click here to add this to my saved trials
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical Prostatectomy
Status: Enrolling
Updated:  12/21/2017
Arizona Oncology Services Foundation
mi
from
Phoenix, AZ
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical Prostatectomy
Status: Enrolling
Updated: 12/21/2017
Arizona Oncology Services Foundation
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical Prostatectomy
Status: Enrolling
Updated:  12/21/2017
Arizona Oncology - Tucson
mi
from
Tucson, AZ
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical Prostatectomy
Status: Enrolling
Updated: 12/21/2017
Arizona Oncology - Tucson
mi
from
Tucson, AZ
Click here to add this to my saved trials
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical Prostatectomy
Status: Enrolling
Updated:  12/21/2017
Auburn Radiation Oncology
mi
from
Auburn, CA
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical Prostatectomy
Status: Enrolling
Updated: 12/21/2017
Auburn Radiation Oncology
mi
from
Auburn, CA
Click here to add this to my saved trials
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical Prostatectomy
Status: Enrolling
Updated:  12/21/2017
Peninsula Medical Center
mi
from
Burlingame, CA
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical Prostatectomy
Status: Enrolling
Updated: 12/21/2017
Peninsula Medical Center
mi
from
Burlingame, CA
Click here to add this to my saved trials
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical Prostatectomy
Status: Enrolling
Updated:  12/21/2017
Radiation Oncology Centers - Cameron Park
mi
from
Cameron Park, CA
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical Prostatectomy
Status: Enrolling
Updated: 12/21/2017
Radiation Oncology Centers - Cameron Park
mi
from
Cameron Park, CA
Click here to add this to my saved trials
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical Prostatectomy
Status: Enrolling
Updated:  12/21/2017
Mercy Cancer Center at Mercy San Juan Medical Center
mi
from
Carmichael, CA
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical Prostatectomy
Status: Enrolling
Updated: 12/21/2017
Mercy Cancer Center at Mercy San Juan Medical Center
mi
from
Carmichael, CA
Click here to add this to my saved trials